Literature DB >> 17088972

SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.

Sateesh Kunigal1, Christopher S Gondi, Meena Gujrati, Sajani S Lakka, Dzung H Dinh, William C Olivero, Jasti S Rao.   

Abstract

Secreted protein acidic and rich in cysteine (SPARC) is highly expressed in human gliomas where it promotes invasion and delays tumor growth, both in vitro and in vivo. SPARC, which interacts at the cell surface, has an impact on intracellular signaling and downstream gene expression changes, which might account for some of its effects on invasion and growth. Additionally in vitro studies demonstrated that SPARC delays growth, increases attachment, and modulates migration of tumor cells in an extracellular matrix-specific and concentration-dependent manner. Because the signaling aspect of this migration is neither well understood nor characterized, we overexpressed SPARC in both the minimally-invasive U87 cell line and in the most aggressive invasive cell line, SNB19. We first performed RT-PCR analysis and observed an upregulation of uPA and its receptor, uPAR. We also observed increased expression levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9). Western blot analysis confirmed these results, and the enzymatic activity of the metalloproteinases and uPA was further supported by zymography. Downstream of the uPA-uPAR interaction, upregulation of PI3-K occurred in cells overexpressing SPARC. Using GST-TRBD, we showed the upregulation of active GTP-bound RhoA, but neither Rac1 nor Cdc42 were activated. The inhibition of uPA and uPAR downregulated PI3-K activity and cell migration, as shown by matrigel invasion assay. A dorsal skin-fold chamber model revealed the high angiogenic activity of SPARC, though the proliferation of SPARC overexpressing cells was unaffected. Our results show that the small GTPase RhoA was a critical mediator of invasion or migration in the uPA-uPAR/PI3-K signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088972      PMCID: PMC1661847     

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  33 in total

Review 1.  Signaling by distinct classes of phosphoinositide 3-kinases.

Authors:  B Vanhaesebroeck; M D Waterfield
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

2.  Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin.

Authors:  I Dumler; V Stepanova; U Jerke; O A Mayboroda; F Vogel; P Bouvet; V Tkachuk; H Haller; D C Gulba
Journal:  Curr Biol       Date:  1999 Dec 16-30       Impact factor: 10.834

3.  Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction.

Authors:  A Kusch; S Tkachuk; H Haller; R Dietz; D C Gulba; M Lipp; I Dumler
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

Review 4.  SPARC, a matricellular protein: at the crossroads of cell-matrix.

Authors:  R A Brekken; E H Sage
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

5.  Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades.

Authors:  S S Lakka; S L Jasti; A P Kyritsis; W K Yung; F Ali-Osman; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.

Authors:  S Mohanam; S L Jasti; S R Kondraganti; N Chandrasekar; Y Kin; G N Fuller; S S Lakka; A P Kyritsis; D H Dinh; W C Olivero; M Gujrati; W K Yung; J S Rao
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

7.  Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.

Authors:  P J Paley; B A Goff; A M Gown; B E Greer; E H Sage
Journal:  Gynecol Oncol       Date:  2000-09       Impact factor: 5.482

8.  Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.

Authors:  P Vajkoczy; M D Menger; R Goldbrunner; S Ge; T A Fong; B Vollmar; L Schilling; A Ullrich; K P Hirth; J C Tonn; P Schmiedek; S A Rempel
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

Review 9.  Angiogenesis: regulators and clinical applications.

Authors:  S Liekens; E De Clercq; J Neyts
Journal:  Biochem Pharmacol       Date:  2001-02-01       Impact factor: 5.858

10.  Role of the PI3K regulatory subunit in the control of actin organization and cell migration.

Authors:  C Jiménez; R A Portela; M Mellado; J M Rodríguez-Frade; J Collard; A Serrano; C Martínez-A; J Avila; A C Carrera
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

View more
  31 in total

1.  Integrin β4 regulates SPARC protein to promote invasion.

Authors:  Kristin D Gerson; Jeffrey R Shearstone; V S R Krishna Maddula; Bruce E Seligmann; Arthur M Mercurio
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

2.  Inhibition of tumor cell migration and invasion through knockdown of Rac1 expression in medulloblastoma cells.

Authors:  Baodong Chen; Yongzhong Gao; Taipeng Jiang; Jianjun Ding; Yanjun Zeng; Ruxiang Xu; Xiaodan Jiang
Journal:  Cell Mol Neurobiol       Date:  2010-11-13       Impact factor: 5.046

3.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Authors:  Stacey L Thomas; Ridwan Alam; Nancy Lemke; Lonni R Schultz; Jorge A Gutiérrez; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

4.  miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling.

Authors:  Kristina Kapinas; Catherine B Kessler; Anne M Delany
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

5.  Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.

Authors:  J J Provost; D Rastedt; J Canine; T Ngyuen; A Haak; C Kutz; N Berthelsen; A Slusser; K Anderson; G Dorsam; M A Wallert
Journal:  Cell Oncol (Dordr)       Date:  2012-01-31       Impact factor: 6.730

6.  In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.

Authors:  Nah Ihm Kim; Ga-Eon Kim; Ji Shin Lee; Min Ho Park
Journal:  Virchows Arch       Date:  2016-12-01       Impact factor: 4.064

7.  Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread.

Authors:  Konrad Franke; Stacy Carl-McGrath; Friedrich-Wilhelm Röhl; Uwe Lendeckel; Matthias Pa Ebert; Marc Tänzer; Matthias Pross; Christoph Röcken
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

Review 8.  Emerging tale of UPR and cancer: an essentiality for malignancy.

Authors:  Younis Mohammad Hazari; Arif Bashir; Ehtisham Ul Haq; Khalid Majid Fazili
Journal:  Tumour Biol       Date:  2016-09-14

9.  Secreted protein acidic and rich in cysteine (SPARC) in human skeletal muscle.

Authors:  Louise H Jørgensen; Stine J Petersson; Jeeva Sellathurai; Ditte C Andersen; Susanne Thayssen; Dorte J Sant; Charlotte H Jensen; Henrik D Schrøder
Journal:  J Histochem Cytochem       Date:  2008-09-15       Impact factor: 2.479

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.